A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
Status:
RECRUITING
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)